The study of the effect of coenzyme Q10 supplementation on depression and cognitive problems in opium-using patients

Evaluating of the Q10 coenzyme additive effect in depression symptoms and cognitive problems change caused by moderate to severe opioid dependency

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250831067061N1

Enrollment

Registered

2025-09-16

Start date

2025-10-22

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to severe opioid-induced depressive disorder. Opioid related disorders

Interventions

Intervention 1: Intervention group: For the proposed study on the effect of coenzyme Q10 (CoQ10) as an adjunctive treatment for moderate to severe depression and cognitive impairments, a dose of 300 m

Eligibility

Sex/Gender

Male

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with no other psychiatric disorders who have developed moderate to severe opium-induced depressive disorder.(HAM>14)

Exclusion criteria

Exclusion criteria: Any underlying psychiatric illness Medical disorders that cause cognitive impairment Decreased level of consciousness accompanied by head trauma Intellectual Disability Disorder History of ECT (Electroconvulsive Therapy) Liver disorder Renal failure

Design outcomes

Primary

Measure	Time frame
Hamilton Depression Rating Scale (HDRS) score. Timepoint: Before intervention initiation and four weeks later. Method of measurement: Hamilton Depression Rating Scale.	—

Secondary

Measure	Time frame
Scores of the response inhibition cognitive test. Timepoint: Before intervention initiation and four weeks later. Method of measurement: Go/No-Go test.;Scores of the selective attention cognitive test. Timepoint: Before intervention initiation and four weeks later. Method of measurement: Stroop test.;Scores of the working memory cognitive test. Timepoint: Before intervention initiation and four weeks later. Method of measurement: n-back test.	—

Measure

Time frame

Scores of the response inhibition cognitive test. Timepoint: Before intervention initiation and four weeks later. Method of measurement: Go/No-Go test.;Scores of the selective attention cognitive test. Timepoint: Before intervention initiation and four weeks later. Method of measurement: Stroop test.;Scores of the working memory cognitive test. Timepoint: Before intervention initiation and four weeks later. Method of measurement: n-back test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara bakhtiari

Mashhad University of Medical Sciences

bakhtiarisara11@gmail.com+98 51 3711 2701

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026